A REVIEW ON BUCCAL FILM LOADED WITH LACOSAMIDE FOR THE TREATMENT OF PARTIAL ONSET SEIZURES
AbstractDespite the introduction of new antiepileptic medicines (AEDs) over the past two decades, more than 30% of epilepsy patients still have refractory disease. Combined administration of AEDs or the use of novel AEDs is the most popular therapeutic choice when surgical therapy cannot be provided, even though a tiny number of these resistant individuals may become seizure free when a new AED is added. Lacosamide (LCM), which has novel modes of action and advantageous safety profiles, is the most recent AED to receive approval in Europe and the USA. This article discusses the efficacy and safety of LCM as determined by phase II and III clinical trials, as well as its molecular mechanisms of action and pharmacokinetic characteristics. It is also explored how LCM compares to other AEDs that are currently on the market.
Article Information
1
36-40
580 KB
348
English
IJP
Nilam Panjiyar *, Ankita Pokhriyal, Pranshu Tangri and Arvind Negi
GRD Institute of Management & Technology, Uttarakhand University, Dehradun, Uttarakhand, India.
Panjiyarnilam39@gmail.com
23 September 2023
13 February 2024
27 February 202
10.13040/IJPSR.0975-8232.IJP.11(2).36-40
29 February 2024
Download